Neoadjuvant HER2+ Articles

Neratinib Improves PFS in HER2+ Metastatic Breast Cancer
Neratinib led to a statistically significant improvement in centrally confirmed progression-free survival compared with lapatinib and capecitabine in patients with HER2-positive metastatic breast cancer who have failed 2 or more prior lines of HER2-directed therapy.
De-Escalation Possible in Curative Setting for HER2+ Breast Cancer
Ciara O’Sullivan, MB, BCh, discusses the need for treatment de-escalation for patients with HER2-positive breast cancer, as well as the challenges that remain in tailoring treatment.
T-DM1 May Provide Less-Toxic Option in Older HER2+ Breast Cancer Population
Akihiko Shimomura, MD, PhD, discusses the rationale for the phase III HERB TEA trial of elderly patients with HER2-positive breast cancer.
Paradigm Evolving in HER2+ Breast Cancer With CNS Mets
Shannon L. Puhalla, MD, discusses some of the advances being made in systemic treatment for patients with brain metastases from breast cancer.
ACE Inhibitor, Beta Blocker Lower Trastuzumab Cardiotoxicity Risk in HER2+ Breast Cancer
In patients with early-stage HER2-positive breast cancer who are being treated with adjuvant trastuzumab and anthracyclines, cardiotoxicity-free survival is longer when they receive prophylactic simultaneous lisinopril or carvedilol.
Palbociclib Combo Active in HER2+ Breast Cancer
The combination of palbociclib and trastuzumab demonstrated safety and efficacy in patients with advanced estrogen receptor–positive/HER2-positive breast cancer.
T-DM1 Likely New Adjuvant Standard in High-Risk HER2+ Breast Cancer
Ado-trastuzumab emtansine reduced the risk of invasive disease recurrence or death by 50% compared with trastuzumab as an adjuvant treatment for patients with HER2-positive early breast cancer who had residual invasive disease following neoadjuvant therapy.
Adjuvant Options Expand in HER2+ Breast Cancer, But Questions Remain
Vik Gorantla, MD, discusses ongoing developments in the adjuvant setting for patients with HER2-positive breast cancer.
Addressing De-Escalation of Treatment in HER2+ Breast Cancer
Data from the NSABP B-52, PERSEPHONE, and APT trials have called into question the optimal duration of treatment for patients with HER2-positive breast cancer.
Neratinib Promising for Early-Stage HER2+ Breast Cancer, But Has Caveats
Mohammed Rahman, MD, discusses ongoing efforts to optimize the use of neratinib in patients with HER2-positive breast cancer.
Publication Bottom Border
Border Publication